Creo Medical updates investors on growth strategy and US opportunity
Published: 02:12 26 Jun 2025 EDT
Creo Medical Group PLC (AIM:CREO) said it was confident of delivering another year of growth as it prepared to host its annual meeting in Bristol on Thursday.
The company, which specialises in surgical endoscopy devices used to treat early-stage cancers, pointed to strong trading in the first quarter and several recent regulatory and commercial milestones.
In a statement ahead of the AGM, chair Kevin Crofton said the group’s core technology products, devices powered by Creo’s proprietary CROMA energy platform, saw a solid start to 2025.
Several new products, including Speedboat UltraSlim, SpydrBlade Flex and Speedboat Notch, have recently launched and are expected to drive increased usage of the platform in hospitals.
The company noted that SpydrBlade Flex had received clearance from the US Food and Drug Administration (FDA).
This allows Creo to begin commercial rollout of the device in the United States, where it will be used in endoscopic procedures to remove pre-cancerous and early-stage cancerous growths from the gastrointestinal tract.
These procedures, known as endoscopic submucosal dissection (ESD), are commonly used in parts of Asia and are beginning to gain traction in the West.
A recent update confirming the availability of reimbursement codes for ESD in the US could help accelerate adoption of Creo’s products, making the procedures more financially viable for hospitals.
Alongside product launches, Creo highlighted continued progress in its partnership with Intuitive, the US surgical robotics group.
The collaboration, focused on Creo’s MicroBlate Flex device, is expected to move into a revenue-generating phase as more US sites complete initial data collection and begin routine use.
The AGM statement also referenced a strategic business review undertaken last year, which led to a sharpened focus on commercialising core technologies and controlling costs.
The company said it remained on track to achieve self-sustaining cash flows, with further growth anticipated from both new and existing hospital customers.
As previously announced, the shareholder meeting also marks the formal stepping down from the main board of two executive directors: David Woods (chief commercial officer) and Christopher Hancock (chief technology officer).
Both continue in their day-to-day roles within the business. These board changes are part of an ongoing governance overhaul designed to streamline leadership and increase board independence.
